glp1 retatrutide and LDL Cholesterol: How GLP-1 Medications Lower Heart Dis – Revolution Health & Wellness What Is Retatrutide? How Does

To help visualise the expected weight loss at different doses, let's look at this comparative table: These percentages represent average weight loss from baseline over a 68-72 week period, based on the SURMOUNT-1 trial for Mounjaro and the STEP-1 trial for Wegovy

Incretin-based agents are not, however, licensed for the treatment of MASLD

About a third of people on cagrilintide (31.6%) achieved 15% weight loss or more, compared to roughly 1 in 20 (4.7%) on placebo

Individual variability : Some patients may respond better than others, depending on genetics and metabolic profile

This is not mandatory, but if you experimented with it during treatment and found it helpful, continuing the practice makes sense

Hypoglycaemia and gastric emptying